Replacing Test Subjects With Computer Models Will Take Cooperation
This article was originally published in The Gray Sheet
More collaboration between device companies and with FDA will be needed to employ sophisticated "virtual patient" computer models to reduce the number of patients needed in clinical trials, says Medtronic statistician Tarek Haddad.
You may also be interested in...
Adaptive device clinical trials, where study is designed in anticipation of midstream changes, are the focus on a new FDA draft guidance. Adaptive trials can reduce the duration and cost of a study without undermining its integrity, but the practice should be applied with caution, FDA says.
At the Regulatory Affairs Professionals Society annual meeting last week, William Hawkins, chairman of the Medical Device Innovation Consortium, said the group is making progress in its first project on computer modeling and simulation, as well as future projects on clinical trial reform, and benefit-risk guidance and patient-centeredness.
The complex calculations of Bayesian statistics are not likely to become standard for FDA device submissions anytime soon, but they could help streamline clinical trials in many more instances, CDRH's top statistics official says